Clinical Trial Update: Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis [Phase 4]

View source ↗

Summary

Phase 4 trial assessing subcutaneous ACTEMRA (tocilizumab) on inflamed atherosclerotic plaques in patients with rheumatoid arthritis was terminated with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Rheumatoid Arthritis

Drugs mentioned

• Actemra (tocilizumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Rheumatoid Arthritis | Phase 4 | Status: TERMINATED | Results posted: 2021-02-23